Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

4 weeks ago

BOCA RATON, Fla., Aug. 23, 2024 ( GLOBE NEWSWIRE ) -- Entero Therapeutics, Inc., ( NASDAQ: ENTO ) , ( "Entero Therapeutics" or the "Company" ) , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal ( GI ) diseases, ...

Ticker	Sentiment	Impact
ENTO	Neutral	25 %